Compare Amphastar Pharmaceuticals Inc (AMPH) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Ryanair Holdings plc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Ryanair Holdings plc trades at $64.3 (market cap $31.76B). The key difference: Ryanair Holdings plc is far larger — about 38.4× Amphastar Pharmaceuticals Inc's market cap, and Ryanair Holdings plc pays a 1.53% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | RYAAY | |
|---|---|---|
Market Cap | $826.08M | $31.76B |
Sector | Health | Industrials |
52-Week High | $30.81 | $73.82 |
52-Week Low | $16.87 | $53.24 |
Enterprise Value | $1.22B | $29.42B |
Dividend Yield | — | 1.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
RYAAY trades at $64.65, up 0.78% today, with a bullish technical signal and strong fundamentals including a 13.9 P/E ratio and 25.37% ROE. Recent earnings beat expectations in three of the last four quarters, and June 2026 traffic grew 7% year-over-year. The company maintains a debt-free balance sheet after repaying its final bond in May 2026, enhancing financial flexibility amid sector volatility.
Outlook remains positive with analyst consensus at 62.5% buy ratings, supported by robust operational execution and 80% fuel hedging for 2027. Key risks include rising operating costs, geopolitical tensions affecting fuel prices, and regulatory scrutiny over seating policies. The stock's valuation appears reasonable relative to earnings growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
